EthionamideThird Party Manufacturing in India

Ethionamide is a prodrug that requires bioactivation by the mycobacterial monooxygenase EthA to exert its antimycobacterial effect. Once activated, it forms an ethionamide-NAD adduct that binds to and inhibits InhA, an enoyl-acyl carrier protein reductase essential for mycolic acid biosynthesis in Mycobacterium tuberculosis. Mycolic acids are long-chain fatty acids that form the hydrophobic outer layer of the mycobacterial cell wall, critical for bacterial survival and virulence. By blocking mycolic acid synthesis, Ethionamide compromises cell wall integrity, leading to bacterial death. This mechanism is analogous to isoniazid, but Ethionamide uses a distinct activation pathway (EthA rather than KatG), making it effective against certain isoniazid-resistant strains. The drug may be bacteriostatic or bactericidal depending on concentration at the infection site and the susceptibility of the infecting organism. Ethionamide is well absorbed orally, crosses the blood-brain barrier achieving CSF concentrations equivalent to plasma, and is extensively metabolized in the liver to active and inactive metabolites. Resistance mechanisms involve mutations in the ethA gene or overexpression of the transcriptional repressor EthR.

Therapeutic Uses

Ethionamide is a second-line antitubercular agent reserved for drug-resistant TB:

• Multidrug-Resistant Tuberculosis (MDR-TB): Ethionamide is a core component in WHO-recommended longer regimens for MDR-TB, used when first-line drugs like isoniazid and rifampicin are ineffective due to resistance.
• Extensively Drug-Resistant TB (XDR-TB): It is included in salvage regimens for XDR-TB where few treatment options remain.
• Isoniazid-Resistant TB: Ethionamide is effective against M. tuberculosis strains resistant to isoniazid, as its activation pathway differs from isoniazid.
• Tuberculous Meningitis: Because Ethionamide crosses the blood-brain barrier well, it is valuable in treating CNS tuberculosis.

Why Manufacturers Choose Ethionamide

Ethionamide is an essential second-line TB drug listed in the WHO Model List of Essential Medicines. The rising global burden of MDR-TB has driven consistent demand for this molecule, particularly in India, China, South Africa, and Eastern European countries. It is manufactured as 250 mg film-coated tablets and requires careful quality control due to its narrow therapeutic index. Indian manufacturers with WHO-GMP certified facilities are well-positioned to supply Ethionamide to both domestic TB control programmes and international procurement agencies such as the Global Drug Facility and Stop TB Partnership. The API synthesis involves thioamide chemistry, which is well within the capability of established Indian bulk drug manufacturers. Export demand remains strong for this molecule across regulated and semi-regulated markets.